Published on
The Food and Drug Administration has approved the oral drug elinzanetant for the treatment of moderate to severe hot flashes due to menopause. It’s a novel nonhormonal drug with dual neurokinin-targeted therapy (NK1 and NK3 receptor antagonist), according to the manufacturer’s press release. Elinzanetant offers another option for patients, in addition to 2 other nonhormonal therapies: NK3 receptor antagonist fezolinetant; and the antidepressant paroxetine. Two phase III trials with a total of 796 menopausal women found elinzanetant significantly reduced the frequency of moderate to severe vasomotor symptoms compared with placebo at week 4.
Availability schedule: Elinzanetant is expected to be available in the United States beginning in November 2025. Full prescribing information is available on the Bayer website.